The prescribing of cardioprotective medications and the impact on survival for patients with peripheral artery disease that undergo intervention
ANZ Journal of Surgery · 2023
DOI: 10.1111/ans.18580 ↗At a glance
Beobachtungsstudie in ANZ Journal of Surgery, 2023. Written by Odette Hart and 2 co-authors. Institution: Department of Surgery, The University of Auckland, Auckland, New Zealand. Major MEDLINE topics: Antihypertensive Agents, Peripheral Arterial Disease, Platelet Aggregation Inhibitors, Hypolipidemic Agents. Cited 3 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY 4.0). Funded by: Reg Worcester Research Scholarship 2023, Professor Philip Walker Vascular Surgery Research Scholarship 2022 and 2021, Royal Australasian College of Surgeons and the Foundation for Surgery.
Abstract (original language)
Background
Cardiovascular disease guidelines recommend that patients with established peripheral artery disease (PAD) are prescribed antihypertensive, lipid‐lowering, and antiplatelet medication to reduce cardiovascular ischaemic events. However, the prescribing of these medications for patients with PAD within New Zealand (NZ) remains undefined.
Methods
This was a retrospective observational cohort study of patients in the Midland region of NZ, that underwent PAD‐related percutaneous and surgical intervention between 1st January 2010 and 31st December 2021. Patient level data was collected. The primary outcome was prescribing of cardioprotective medications either before or within 1 year of incident procedure. Secondary outcome was overall survival.
Results
There were 2547 patients included. Antihypertensive prescription occurred in 80.7%, lipid‐lowering in 77.4% and antithrombotic in 89.9%. Concomitant ischaemic heart disease increased prescription of cardioprotective medications. Women were prescribed less lipid‐lowering medication compared to men. Māori men were prescribed less antiplatelet medication compared to non‐Māori men. On univariate analysis lipid‐lowering and antiplatelet medication showed survival advantage, while antihypertensive and anticoagulation did not. After adjustment for age, sex, end stage renal failure and presence of chronic limb‐threatening ischaemia, best medical therapy was associated with better survival (HR 0.88, 95% CI 0.79–0.98, P = 0.02).
Conclusion
This study highlights areas of deficiency in prescribing of cardioprotective medication in this high‐risk group. These could be targets for national quality improvement initiatives.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Surgery, The University of Auckland, Auckland, New Zealand.
- Department of Vascular Surgery, Waikato District Health Board, Hamilton, New Zealand.
ORCID profiles: Odette Hart, Manar Khashram
Funding
- Reg Worcester Research Scholarship 2023
- Professor Philip Walker Vascular Surgery Research Scholarship 2022 and 2021
- Royal Australasian College of Surgeons and the Foundation for Surgery
Cite
APA
Hart, O., Xue, N., & Khashram, M. (2023). The prescribing of cardioprotective medications and the impact on survival for patients with peripheral artery disease that undergo intervention. ANZ Journal of Surgery. https://doi.org/10.1111/ans.18580
Vancouver
Hart O, Xue N, Khashram M. The prescribing of cardioprotective medications and the impact on survival for patients with peripheral artery disease that undergo intervention. ANZ Journal of Surgery. 2023. doi:10.1111/ans.18580
BibTeX
@article{Hart2023,
author = {Hart, Odette and Xue, Nicole and Khashram, Manar},
title = {The prescribing of cardioprotective medications and the impact on survival for patients with peripheral artery disease that undergo intervention},
journal = {ANZ Journal of Surgery},
year = {2023},
doi = {10.1111/ans.18580}
}
EUVIMED